Nasdaq
MIST Hits A Milestone: FDA Approves First-Ever Self-Administered Nasal Spray For PSVT
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has received FDA approval for its first commercial product, CARDAMYST nasal spray, for the conversion of acute symptomatic episodes of paroxysmal ...
Healio
FDA approves self-administered nasal spray for paroxysmal supraventricular tachycardia
Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...
WebMD
Cardamyst: FDA Approves First Rapid-Acting Self-Use Nasal Spray for Sudden Fast Heartbeats (PSVT)
What Is Cardamyst, and Why Does It Matter? Cardamyst (etripamil) is a new nasal spray for treating sudden episodes of fast heartbeats, known as paroxysmal supraventricular tachycardia (PSVT), and ...
Benzinga.com
Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats
The approval marks Cardamyst as the first FDA-approved treatment in over 30 years for more than 2 million Americans with PSVT. Cardamyst nasal spray is a novel and rapid-acting calcium channel blocker ...
Seeking Alpha
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
FiercePharma
Milestone wins 1st-ever FDA approval with green light for heart arrhythmia nasal spray
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given Milestone Pharmaceuticals its first FDA approval in its 22-year history. The ...
Nasdaq
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first ...